uniQure (NASDAQ: QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

Qure advances its pathology-shifting AMT-130 therapy for Huntington's disease; pivotal data and commercial launch prep target 2025 milestones.

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $37.7 million in its second quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 69 cents.

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 top ...

Qure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 ...

Qure (NASDAQ:QURE) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. The consensus EPS ...

Investing.com - uniQure N.V. (NASDAQ: QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s ...

Qure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET LEXINGTON, Mass. and AMSTERDAM, July 22, 2025N.V.

Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.

uniQure N.V. (QURE) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.